Mechanism of synergy of levamisole and fluorouracil: Induction of human leukocyte antigen class I in a colorectal cancer cell line

Journal of the National Cancer Institute

Volumn 87, Issue 7, 1995, Pages 489-496

  Abdalla, Elmuataz E ^a   Blair, G Eric ^a   Jones, Richard A ^a   Sue ling, Henry M ^a   Johnston, David ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF KHARTOUM   (Sudan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; HLA ANTIGEN; LEUKOCYTE ANTIGEN; LEVAMISOLE;

ARTICLE; COLORECTAL CANCER; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; RNA SYNTHESIS;

BETA 2-MICROGLOBULIN; BLOTTING, NORTHERN; COLORECTAL NEOPLASMS; DNA PROBES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; FLUOROURACIL; GENES, MHC CLASS I; HUMAN; LEVAMISOLE; RNA, MESSENGER; RNA, NEOPLASM; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0028908636     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/87.7.489     Document Type: Article

References (38)

1. Moertel CG: Accomplishments in surgical adjuvant therapy for large bowel cancer. Cancer 70(5 Suppl): 1364-1371, 1992.
2. Journal of the National Cancer Institute, Vol. 87, No. 7, April 5, 1995.
3. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma [see comment citations in Medline]. N Engl J Med 322:352-358, 1990.
4. Windle R, Bell PR, Shaw D: Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg74:569-572,1987.
5. Grem JL: Levamisole as a therapeutic agent for colorectal carcinoma. Cancer Cells 2:131-137, 1990.
6. Tripodi D, Parks LC, Brugmans J: Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N Engl J Med289:354-357,1973.
7. Miwa H, Kawai T, Nakahara H, et al: Decrease in cell mediated immunity by surgical intervention and its prevention by levamisole. Int J Im-munopharmacol 2:31-36, 1980.
8. Windle R, Wood RF, Bell PR: The effect of levamisole on postoperative immunosuppression. BrJ Surg 66:507-509, 1979.
9. Symoens J, De Créé J, Van Beoer W, et al: Levamisole. In Pharmacological and Biochemical Properties of Drag Substances (Goldberg ME, ed). Washington DC: American Pharmaceutical Association, Academy of Pharmaceutical Sciences, 1979, pp 407-464.
10. Amery WK, Christian H: Levamisole. In Immune Modulation Agents and Their Mechanisms (Femchel RL, Chrigos MA, eds). New York: Marcel Dekker, 1984, pp 383-408.
11. Stevenson HC, Green I, Hamilton JM, et al: Levamisole: known effects on the immune system, clinical results, and future application to the treatment of cancer. J Clin Oncol 9:2052-2066, 1991.
12. Myers CE: The pharmacology of the fluoropyrimidines. Pharmacol Rev33:1-15,1981.
13. Greenhalgh DA, Parish JH: Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells. BrJ Cancer 61:415-419,1990.
14. Wu XP, Dolnick BJ: 5-Fluorouracil alters dihydrofolate reductase pre-mRNA splicing as determined by quantitative polymerase chain reaction. Mol Pharmacol 44:22-29, 1993.
15. Maas IW, Boven E, Pinedo H, et al: The effects of y-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. Int J Cancer 48:749-756, 1991.
16. Goodrich KH, Alvarez X, Holcombe RF: Effect of levamisole on major histocompatibility complex class I expression in colorectal and breast carcinoma cell lines. Cancer 72:225-230, 1993.
17. Kaklamanis L, Hill A: MHC loss in colorectal tumors: evidence for im-munoselection? Cancer Surv 13:155-171, 1992.
18. Garrido F, Cabrera T, Concha A, et al: Natural history of HLA expression during tumour development. ImmunolToday 14:491-499, 1993.
19. Kufe DW, Major PP, Egan EM, et al: 5-Fluoro-2'-deoxyuridine incorporation in L1210 DNA. J Biol Chem 256:8885-8887, 1981.
20. Kase S, Kubota T, Watanabe M, et al: Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Anticancer Res 13:369-374, 1993.
21. Peters GJ, Lankelma J, Kok RM, et al: Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol 31:269-276, 1993.
22. Seymour CB, Mothersill C: Chemotherapy agents and the induction of late lethal defects. Anticancer Res 11:1605-1608, 1991.
23. Luyckx M, Rousseau F, Cazin M, et al: Pharmacokinetics of levamisole in healthy subjects and cancer patients. Eur J Drug Metab Pharmacoktnet 7:247-254,1982.
24. Grem JL, Allegra CJ: Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. J Natl Cancer Inst 81:1413-1417, 1989.
25. Zajdel-Blair ME, Blair GE, Bennich H: Purification and characterization of the messenger RNA for the heavy chain of rat immunoglobulin E. Nucleic Acids Res 9:4547-4555, 1981.
26. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: a Laboratory Manual (2nd ed). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
27. Sood AK, Pereira D, Weissman SM: Isolation and partial nucleotide sequence, of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer. Proc Natl Acad Sci U S A 78:616-620,1981.
28. Minty AJ, Alonso S, Guenet JL, et al: Number and organization of actin-related sequences in the mouse genome. J Mol Biol 167:77-101, 1983.
29. Oren M: The p53 cellular tumor antigen: gene structure, expression and protein properties. Biochim Biophys Acta 823:67-78, 1985.
30. Trowsdale J, Young JA, Kelly AP, et al: Structure, sequence and polymorphism in the HLA-D region. Immunol Rev 85:5-43, 1985.
31. Browne H, Smith G, Beck S, et al: A complex between the MHC class I homologue encoded by human cytomegalovirus and ffe-microglobulin. Nature 347:770-772, 1990.
32. Chen-Kiang S, Lavery DJ: Pulse labeling of heterogeneous nuclear RNA in isolated nuclei. Methods Enzymol 180:82-96, 1989.
33. Berger SL: The use of Cerenkov radiation for monitoring reactions performed in minute volumes: examples from recombinant DNA technology. Anal Biochem 136:515-519, 1984.
34. Jefferies WA, MacPherson GG: Expression of the W6/32 HLA epitope by cells of rat, mouse, human and other species: critical dependence on the interaction of specific MHC heavy chains with human or bovine Pstn icroglobulin. EurJ Immunol 17:1257-1263, 1987.
35. Hunt P, Zsebo KM, Hokom MM, et al: Evidence that stem cell factor is involved in the rebound thrombocytosis that follows 5-fluorouracil treatment. Blood 15:904-911, 1992.
36. Balaji KN, Nayak R: Effect of 5-fluorouracil on interleukin-2 expression. Biochem Biophys ResCommun 187:305-309, 1992.
37. Onodera H, Somers S, Guillou PJ: Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer. BrJ Cancer 62:1042-1046, 1990.
38. Torelii U: An overlooked aspect of the mechanism of action of most antineoplastic drugs: the inhibition of macromolecular RNA metabolism. Eur J Cancer 13:1363-1367, 1977.